ImmunoPrecise Antibodies Advances Therapeutic Innovation With Rabbit Antibody Developments, Says Rabbit B Cell Select Drives Clinical Breakthroughs In Cancer Treatment
Portfolio Pulse from Benzinga Newsdesk
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) has announced clinical progress with rabbit monoclonal antibodies developed using its B Cell Select® platform. These antibodies are being used by OncoResponse Inc. in cancer treatment trials, highlighting IPA's leadership in therapeutic antibody development.
September 26, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) has made significant clinical progress with its rabbit monoclonal antibodies, developed using the B Cell Select® platform. This advancement, in collaboration with OncoResponse Inc., positions IPA as a leader in therapeutic antibody development.
The announcement of clinical progress with rabbit monoclonal antibodies using the B Cell Select® platform is a positive development for IPA. This positions the company as a leader in therapeutic antibody development, likely boosting investor confidence and potentially impacting stock prices positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100